Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies.
Biomark Med
; 9(4): 363-75, 2015.
Article
em En
| MEDLINE
| ID: mdl-25808440
ABSTRACT
Patients with metastatic colorectal cancer have a very poor prognosis. Incorporation of targeted molecular therapies, such as the anti-EGFR receptor monoclonal antibodies cetuximab and panitumumab, into treatment regimens has improved outcomes for patients with wild-type RAS tumors. Yet, response rates remain low and overall survival times are short. Increased understanding of oncogenic signaling pathways within the tumor, and how these are regulated by the inflammatory tumor microenvironment, is a priority to facilitate the development of biomarkers to better guide the use of existing therapies and to develop new ones. Here, we review recent preclinical and clinical progress in the development of biomarkers for predicting response to anti-EGFR therapy in metastatic colorectal cancer.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Colorretais
/
Biomarcadores Tumorais
/
Proteínas Proto-Oncogênicas
/
Proteínas ras
/
Terapia de Alvo Molecular
/
Receptores ErbB
Tipo de estudo:
Prognostic_studies
Idioma:
En
Revista:
Biomark Med
Ano de publicação:
2015
Tipo de documento:
Article
País de afiliação:
Irlanda